trending Market Intelligence /marketintelligence/en/news-insights/trending/2p5GBqYZEENdc5yUmOxbxg2 content esgSubNav
In This List

FibroGen plans follow-on offering of common stock

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


FibroGen plans follow-on offering of common stock

FibroGen Inc. plans to offer and sell up to $300 million of its common stock in an underwritten follow-on offering.

The company expects to grant the underwriters an option to buy additional common shares.

Net proceeds will be used to fund the expansion of product development, manufacturing and commercialization activities as well as for general corporate purposes.

Goldman Sachs & Co. LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering.